Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "8th Annual ...
GenVec, Inc. (Nasdaq: GNVC) announced today that it is lowering its operating costs to conserve capital including eliminating 23 positions, or...
Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the three months and six months ended June 30, 2012. GenVec reported a net loss of...
GenVec, Inc. (Nasdaq: GNVC) will report financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012, before the U.S....
GenVec, Inc. (NASDAQ: GNVC) today announced that the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) has issued a ...
GenVec, Inc. (NASDAQ: GNVC) announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its...
GenVec, Inc. (NASDAQ: GNVC) today announced that effective May 23, 2012 Cynthia Collins has been appointed as President and Chief Executive Officer....
Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the first quarter ended March 31, 2012. GenVec reported a net loss of $3.2 million, ...
GenVec, Inc. (Nasdaq: GNVC) will report financial results for the first quarter ended March 31, 2012 on Thursday, May 10, 2012, before the U.S....
GenVec, Inc. (NASDAQ: GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in...
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of...
GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone...
Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December...
GenVec, Inc. (Nasdaq: GNVC) will report financial results for the fourth quarter and year ended December 31, 2011 on Thursday, March 15, 2012, before ...
GenVec, Inc. (NASDAQ: GNVC) today announced that Douglas J. Swirsky, Senior Vice President and Chief Financial Officer, will present at the ROTH 24th ...
GenVec, Inc. (Nasdaq: GNVC), a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, ...
GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the...
GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the third quarter ended September 30, 2011. GenVec reported a net loss of $1.5...
GenVec, Inc. (Nasdaq: GNVC) will report financial results for the third quarter of 2011 on Wednesday, November 9, 2011, before the U.S. financial...
GenVec, Inc. (NASDAQ:GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting...
GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting...
GenVec, Inc. (NASDAQ: GNVC) today announced its financial results for the three months and six months ended June 30, 2011. "During the second quarter ...
GenVec, Inc. (Nasdaq: GNVC) announced that Adel A.F. Mahmoud, M.D., Ph.D. and Edward M. Connor, Jr., M.D. were elected to the Company's Board of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.